Overview

A Study to Assess the Tolerability of a Single Dose of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Status:
Completed
Trial end date:
2015-08-21
Target enrollment:
Participant gender:
Summary
This study assesses the tolerability of a single dose of gefapixant (AF-219) in participants with idiopathic pulmonary fibrosis (IPF). Six eligible participants will receive a single 150 mg dose of gefapixant and undergo tolerability and PK assessments.
Phase:
Phase 2
Details
Lead Sponsor:
Afferent Pharmaceuticals, Inc.